Abram Bieliauskas, MPP is Director of U.S. Federal Policy at Pfizer, where he leads efforts to advance coverage, coding, and payment strategies for medicines, vaccines, and emerging prescription digital therapeutics (PDTs) under federal programs including Medicare, Medicaid, and the federal marketplace. He led Pfizer’s policy strategy to secure Medicare coverage for PDTs, culminating in CMS finalizing codes for Digital Mental Health Technologies—creating a stable revenue pathway and unlocking access to a new treatment modality for Medicare patients. Previously, Abram held policy roles at The ALS Association, Pancreatic Cancer Action Network, and the U.S. Congress. At the ALS Association, he led the COVID-19 response, advocating for telehealth flexibilities to protect people with ALS and support provider access, and led efforts to introduce and successfully pass legislation eliminating the Social Security Disability Insurance waiting period for ALS patients. He holds a Master of Public Policy from the London School of Economics and a Bachelor of Arts in Pre-Law Political Science from Ohio University.